NASDAQ:AXSM

Axsome Therapeutics Stock Forecast, Price & News

$75.90

-0.02 (-0.03 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$74.39

Now: $75.90▼

$77.05

50-Day Range

$75.59

MA: $80.03▼

$86.52

52-Week Range

$35.44

Now: $75.90▼

$109.53

Volume250,556 shs

Average Volume275,480 shs

Market Capitalization$2.83 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.59

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

MarketRank^™

Overall MarketRank^™

1.59 out of 5 stars

Medical Sector

315th out of 1,926 stocks

Pharmaceutical Preparations Industry

166th out of 773 stocks

4.4 Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $146.80, Axsome Therapeutics has a forecasted upside of 93.4% from its current price of $75.90.
Amount of Analyst Coverage
Axsome Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Axsome Therapeutics has received 351 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Axsome Therapeutics has received 294 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Axsome Therapeutics has received 54.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote “Outperform” if you believe AXSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 26.00% of the stock of Axsome Therapeutics is held by insiders.
Percentage Held by Institutions
63.64% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to decrease in the coming year, from ($2.65) to ($3.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 14.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AXSM

Previous Symbol

CUSIPN/A

CIK1579428

Webaxsome.com

Phone212-332-3241

Employees53

Debt

Debt-to-Equity Ratio0.36

Current Ratio9.99

Quick Ratio9.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.18 per share

Price / Book14.65

Profitability

EPS (Most Recent Fiscal Year)($2.01)

Net Income$-68,350,000.00

Net MarginsN/A

Return on Equity-62.33%

Return on Assets-47.87%

Miscellaneous

Outstanding Shares37,344,000

Market Cap$2.83 billion

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$75.90

-0.02 (-0.03 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

How has Axsome Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXSM stock has increased by 3.1% and is now trading at $75.90.
View which stocks have been most impacted by COVID-19.

Is Axsome Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 sell rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Axsome Therapeutics?

Wall Street analysts have given Axsome Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axsome Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Axsome Therapeutics' CEO?

1,448 employees have rated Axsome Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Axsome Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Axsome Therapeutics.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.01.
View Axsome Therapeutics' earnings history.

What price target have analysts set for AXSM?

12 equities research analysts have issued 1-year price targets for Axsome Therapeutics' stock. Their forecasts range from $66.00 to $210.00. On average, they anticipate Axsome Therapeutics' share price to reach $146.80 in the next twelve months. This suggests a possible upside of 93.4% from the stock's current price.
View analysts' price targets for Axsome Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Axsome Therapeutics' key competitors?

Some companies that are related to Axsome Therapeutics include Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Galapagos (GLPG), Allakos (ALLK) and Schrödinger (SDGR).
View all of AXSM's competitors.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:

Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 52, Pay $761.25k)
Mr. Nick Pizzie CPA, M.B.A., Chief Financial Officer (Age 45, Pay $520k)
Mr. David C. Marek, Chief Commercial Officer (Age 55, Pay $424.33k)
Mr. Mark L. Jacobson, COO & Sec. (Age 37)
Dr. Cedric O'Gorman M.B.A., M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 45)
Dr. Amanda Jones Pharm.D., Sr. VP of Clinical Research (Age 37)
Ms. Lori Englebert, Sr. VP of Commercial & Bus. Devel.
Joseph Debrah-Afful CPA, M.B.A., Director of Fin.

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.39%), Baldwin Brothers Inc. MA (0.07%), Vigilare Wealth Management (0.01%) and Signature Estate & Investment Advisors LLC (0.01%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie.
View institutional ownership trends for Axsome Therapeutics.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vigilare Wealth Management, Signature Estate & Investment Advisors LLC, and Baldwin Brothers Inc. MA. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie.
View insider buying and selling activity for Axsome Therapeutics or or view top insider-buying stocks.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $75.90.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $2.83 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Axsome Therapeutics employs 53 workers across the globe.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is axsome.com.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here